ALLOGENE THERAPEUTICS INC (ALLO) Stock Earnings & Estimates
USA - NASDAQ:ALLO - US0197701065 - Common Stock
1.17 USD
+0.01 (+0.86%)
1.2 USD
+0.03 (+2.56%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 240K -99.38% | 95K -60.42% | 22K -76.84% | 10.2K -53.64% | 20.4K 100.00% | 29.121M 142,650.00% | 166.34M 471.20% | 387.06M 132.69% | 707.41M 82.76% | 988.23M 39.70% | 1.27B 28.51% | |
| EBITDA YoY % growth | -321.15M -30.90% | -300.293M 6.49% | -243.843M 18.80% | -227.825M 6.57% | -224.708M 1.37% | -298.676M -32.92% | -290.639M 2.69% | -219.188M 24.58% | -63.668M 70.95% | N/A | N/A | |
| EBIT YoY % growth | -335.45M -31.14% | -314.492M 6.25% | -257.482M 18.13% | -236.684M 8.08% | -247.605M -4.61% | -273.597M -10.50% | -204.691M 25.19% | -27.831M 86.40% | 228.19M 919.91% | 405.14M 77.55% | 617.83M 52.50% | |
| Operating Margin | -139,770.83% | -331,044.21% | -1,170,372.73% | -2,320,435.50% | -1,213,750.90% | -939.52% | -123.06% | -7.19% | 32.26% | 41.00% | 48.65% | |
| EPS YoY % growth | -2.32 -22.75% | -2.01 13.36% | -1.33 33.83% | -1.01 24.04% | -0.94 6.85% | -1.03 -9.35% | -0.73 29.29% | 0.38 151.87% | 2.13 464.86% | 4.26 100.00% | 6.06 42.11% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 29.34% | -0.22 20.70% | -0.22 20.86% | -0.23 -0.39% | -0.24 -5.50% | -0.24 -9.96% |
| Revenue Q2Q % growth | 3.397K | 3.397K | ||||
| EBITDA Q2Q % growth | -53.747M -6.14% | -51.842M -10.65% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.778M 10.27% | -56.91M 5.92% | -54.755M 16.01% | -57.353M -5.36% | -60.456M -10.37% | -61.855M -8.69% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.23 34.29% | -0.28 | 0.05 | 17.55% |
| Q1 2025 Q2Q % growth | -0.28 26.32% | -0.30 | 0.02 | 5.26% |
| Q4 2024 Q2Q % growth | -0.28 34.88% | -0.34 | 0.06 | 17.64% |
| Q3 2024 Q2Q % growth | -0.32 13.51% | -0.34 | 0.02 | 4.75% |
| Q2 2024 Q2Q % growth | -0.35 33.96% | -0.35 | 0.00 | 1.21% |
| Q1 2024 Q2Q % growth | -0.38 44.12% | -0.42 | 0.04 | 8.99% |
| Q4 2023 Q2Q % growth | -0.43 34.85% | -0.46 | 0.03 | 6.14% |
| Q3 2023 Q2Q % growth | -0.37 36.21% | -0.53 | 0.16 | 30.17% |
| Q2 2023 Q2Q % growth | -0.53 -1.92% | -0.60 | 0.07 | 11.77% |
| Q1 2023 Q2Q % growth | -0.68 -21.43% | -0.63 | -0.05 | -8.03% |
| Q4 2022 Q2Q % growth | -0.66 -22.22% | -0.71 | 0.05 | 7.43% |
| Q3 2022 Q2Q % growth | -0.58 -1.75% | -0.66 | 0.08 | 11.76% |
| Q2 2022 Q2Q % growth | -0.52 1.89% | -0.62 | 0.10 | 16.43% |
| Q1 2022 Q2Q % growth | -0.56 -124.00% | -0.59 | 0.03 | 4.62% |
| Q4 2021 Q2Q % growth | -0.54 -1.89% | -0.61 | 0.07 | 11.52% |
| Q3 2021 Q2Q % growth | -0.57 -9.62% | -0.57 | 0.00 | 0.01% |
| Q2 2021 Q2Q % growth | -0.53 | -0.56 | 0.03 | 4.97% |
| Q1 2021 Q2Q % growth | -0.25 50.00% | -0.46 | 0.21 | 46.19% |
| Q4 2020 Q2Q % growth | -0.53 8.62% | -0.57 | 0.04 | 6.80% |
| Q3 2020 Q2Q % growth | -0.52 -4.00% | -0.55 | 0.03 | 5.21% |
| Q2 2020 Q2Q % growth | -0.53 -29.27% | -0.55 | 0.02 | 4.01% |
| Q1 2020 Q2Q % growth | -0.50 -56.25% | -0.59 | 0.09 | 15.10% |
| Q4 2019 Q2Q % growth | -0.58 | -0.70 | 0.12 | 16.77% |
| Q3 2019 Q2Q % growth | -0.50 | -0.55 | 0.05 | 8.94% |
| Q2 2019 Q2Q % growth | -0.41 | -0.47 | 0.06 | 13.18% |
| Q1 2019 Q2Q % growth | -0.32 | -0.44 | 0.12 | 26.59% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.856K | -1.856K | -100.00% | |
| Q1 2025 Q2Q % growth | -100.00% | 1.856K | -1.856K | -100.00% |
| Q4 2024 Q2Q % growth | -100.00% | 14.28K | -14.28K | -100.00% |
| Q3 2024 Q2Q % growth | -100.00% | 13.189K | -13.189K | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 17.248K | -17.248K | -100.00% |
| Q1 2024 Q2Q % growth | 22K -57.69% | 9.792K | 12.208K | 124.67% |
| Q4 2023 Q2Q % growth | 21K -58.00% | 24.041K | -3.041K | -12.65% |
| Q3 2023 Q2Q % growth | 43K -14.00% | 12.781K | 30.219K | 236.45% |
| Q2 2023 Q2Q % growth | 44K -51.11% | 19.268K | 24.732K | 128.36% |
| Q1 2023 Q2Q % growth | 52K -13.33% | 10.914K | 41.086K | 376.45% |
| Q4 2022 Q2Q % growth | 50K | 61.404K | -11.404K | -18.57% |
| Q3 2022 Q2Q % growth | 50K | 14.912K | 35.088K | 235.29% |
| Q2 2022 Q2Q % growth | 90K 125.00% | 5.661K | 84.339K | 1,489.83% |
| Q1 2022 Q2Q % growth | 60K -99.84% | 60K | % | |
| Q4 2021 Q2Q % growth | 50K | -6.324K | 56.324K | 890.64% |
| Q3 2021 Q2Q % growth | 50K | 14.576K | 35.424K | 243.03% |
| Q2 2021 Q2Q % growth | 40K | 235.814K | -195.814K | -83.04% |
| Q1 2021 Q2Q % growth | 38.35M | 13.102M | 25.248M | 192.70% |
| Q4 2020 Q2Q % growth | 3.23M | -3.23M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.1% | 11.02% | 0% | 5.7% |
| Revenue | -100% | -100% | -9.99% | 83.15% |